Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
June 23, 2020
By: Ted Mathias and Rebecca Clegg
BioProcess Online / Biosimilar Development
BioProcess Online and Biosimilar Development published "Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins," an article written by Axinn partnerTed Mathias and associate Rebecca Clegg.
Click to access the article on BioProcess Online and Biosimilar Development.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property
Chambers Merger Control 2025 Guide
Byline Articles
Antitrust
Navigating the Hart-Scott-Rodino Act in 2025
Webinar
Antitrust
French Competition Enforcement in the New EU Paradigm
Axinn Viewpoints
Antitrust